Publications by authors named "Mark Ledeboer"

Claim this Profile
T
Transplanted organoids empower human preclinical assessment of drug candidate for the clinic.
Amy D Westerling-Bui, Eva Maria Fast, Thomas W Soare, Srinivasan Venkatachalan, Michael DeRan, Mark W Ledeboer

Sci Adv· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of Highly Selective Inhibitors of CDK5.
Matthew H Daniels, Goran Malojcic, Susan L Clugston, Brett Williams, Marie Coeffet-Le Gal, Mark Ledeboer

J Med Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis of TRPC4 regulation by calmodulin and pharmacological agents.
Deivanayagabarathy Vinayagam, Dennis Quentin, Jing Yu-Strzelczyk, Oleg Sitsel, Felipe Merino, Mark W Ledeboer

Elife· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model.
Maolin Yu, Mark W Ledeboer, Matthew Daniels, Goran Malojcic, Thomas T Tibbitts

ACS Med Chem Lett· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.
Luc J Farmer, Michael P Clark, Michael J Boyd, Emanuele Perola, Steven M Jones, Mark W Ledeboer

ACS Med Chem Lett· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza.
Upul K Bandarage, Michael P Clark, Emanuele Perola, Huai Gao, Marc D Jacobs, Mark W Ledeboer

ACS Med Chem Lett· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
Luc J Farmer, Mark W Ledeboer, Thomas Hoock, Michael J Arnost, Randy S Bethiel

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
Philip N Collier, David Messersmith, Arnaud Le Tiran, Upul K Bandarage, Christina Boucher, Mark W Ledeboer

J Med Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.
Michael J Boyd, Upul K Bandarage, Hamilton Bennett, Randal R Byrn, Ioana Davies, Mark W Ledeboer

Bioorg Med Chem Lett· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Randal A Byrn, Steven M Jones, Hamilton B Bennett, Chris Bral, Michael P Clark, Mark W Ledeboer

Antimicrob Agents Chemother· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual p38/JNK mitogen activated protein kinase inhibitors prevent ozone-induced airway hyperreactivity in guinea pigs.
Kirsten C Verhein, Francesco G Salituro, Mark W Ledeboer, Allison D Fryer, David B Jacoby

PLoS One· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
Michael P Clark, Mark W Ledeboer, Ioana Davies, Randal A Byrn, Steven M Jones

J Med Chem· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
Tiansheng Wang, Mark W Ledeboer, John P Duffy, Francesco G Salituro, Albert C Pierce

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Mark W Ledeboer, Albert C Pierce, John P Duffy, Huai Gao, David Messersmith

Bioorg Med Chem Lett· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole.
Tiansheng Wang, John P Duffy, Jian Wang, Summer Halas, Francesco G Salituro, Mark W Ledeboer

J Med Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.
Jingrong Cao, Huai Gao, Guy Bemis, Francesco Salituro, Mark Ledeboer

Bioorg Med Chem Lett· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asymmetric Reduction. A Convenient Method for the Reduction of Alkynyl Ketones.
Kathlyn A. Parker, Mark W. Ledeboer

J Org Chem· May 1996

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis